European CHMP Adopts Positive Opinion on Gilead’s Type II Variation Application for Truvada® for Reducing the Risk of Sexually Acquired HIV
Go back to European CHMP Adopts Positive Opinion on Gilead’s Type II Variation Application for Truvada® for Reducing the Risk of Sexually Acquired HIV| Gilead Sciences (NASDAQ: GILD) | Delayed: 150.11 -0.78 (0.52%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $150.89 | 52 Week High | $108.63 | |||
| Open | $150.56 | 52 Week Low | $71.39 | |||
| Day High | $153.23 | P/E | 82.93 | |||
| Day Low | $149.57 | EPS | $1.81 | |||
| Volume | 16,453,710 | |||||
